Adaptive Biotechnologies
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $46,435 | $43,190 | $41,873 | $45,784 |
Gross Profit | 29,768 | 21,088 | 23,822 | 20,776 |
EBITDA | -24,567 | -38,549 | -39,326 | -61,063 |
EBIT | -29,158 | -43,552 | -44,540 | -66,455 |
Net Income | -32,071 | -46,222 | -47,507 | -69,441 |
Net Change In Cash | 46,435 | 43,190 | 41,873 | 45,784 |
Free Cash Flow | -27,409 | -19,032 | -39,864 | -28,230 |
Cash | 38,084 | 59,824 | 71,233 | 65,063 |
Basic Shares | 147,516 | 147,414 | 145,787 | 144,900 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $170,276 | $185,308 | $154,344 | $98,382 |
Gross Profit | 94,723 | 127,399 | 105,043 | 75,852 |
EBITDA | -189,273 | -167,983 | -193,345 | -144,345 |
EBIT | -211,504 | -196,130 | -214,326 | -156,083 |
Net Income | -225,250 | -142,464 | -205,611 | -139,637 |
Net Change In Cash | 170,276 | 185,308 | 154,344 | 98,382 |
Cost of Revenue | -48,775 | 15,629 | 26,860 | |
Free Cash Flow | -167,021 | -200,294 | -254,473 | -168,486 |
Cash | 65,063 | 90,030 | 139,065 | 123,436 |
Basic Shares | 144,383 | 142,515 | 140,354 | 131,216 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.22 |
2024-06-30 | -$0.31 |
2024-03-31 | -$0.33 |
2023-12-31 | -$0.30 |
